A clinical research of siddha medicine in the management of Psoriasis (Kalanjagapadai)

An open clinical trial of Siddha drug Karunchoorai chooranam (Internal medicine) and Kodiveli Thylam (External Medicine) in the treatment of kalanjagapadai (Psoriasis)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/06/008923

Enrollment

Registered

2017-06-28

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- kalanjagapadai (Psoriasis)

Interventions

Intervention1: karunchoorai chooranam (internal) kodiveli thylam ( external): 2 gram of karunchoorai chooranam will be adminstered orally twice a day, 50 ml of kodiveli thylam (external) will be issu

Eligibility

Inclusion criteria

Inclusion criteria: 1.Erythema 2.Thickness 3.Scaling 4.Itching; with or without itching 5.Auspitz sign + 6.Candle crease sign +

Exclusion criteria

Exclusion criteria: 1.Psoriatic arthropaty 2.pregnancy and lactation 3.Psoriasis with evidence of any other skin disease 4.Evidence of secondary infection 5.Leprosy 6.Systemic illness

Design outcomes

Primary

Measure	Time frame
GOOD OUTCOME-Clearence of lesions and reduction of PASI score from 3,4 to 1,2 MODERATE OUTCOME- Partial clearence of lesions and reduction of PASI score from 3,4 to 1,2 POOR/NIL-No clearence of lesions or no reduction of PASI ScoreTimepoint: 48 days	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDR S P KOPPERUNDEVI

National Institute of Siddha

rvmahalakshmi85@gmail.com9444519975

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026